Literature DB >> 29937538

Pulmonary Fat Embolism and Coronary Amyloidosis.

Veronica Lever1, Francesco Erdini1, Claudio Ghimenton1, Luca Novelli2, Matteo Brunelli1, Mattia Barbareschi3, Guido Mazzoleni4, Elisa Vermiglio5, Alessandro Mantovani6, Luca Cima1, Giovanni Valotto1, Albino Eccher1.   

Abstract

BACKGROUND Fat embolism syndrome is a well-known complication in orthopedic and trauma surgery, caused by a massive release of fat into the circulation that can lead to cardiopulmonary insufficiency and multiorgan failure. CASE REPORT We present the case of a 72-year-old man with osteoarthritis who underwent an elective right cementless total hip arthroplasty. Two hours after surgery, the patient lost consciousness and was found hypotensive and with reduced oxygen saturation, with a severe right heart dilatation at echocardiographic evaluation. Death occurred after cardiopulmonary resuscitation attempts. Post-mortem microscopic examination revealed that the final cause of death was pulmonary fat embolism associated with coronary amyloidosis and atherosclerosis. CONCLUSIONS This case called our attention on the sudden onset of fat embolism syndrome after arthroplasty and the insidious nature of amyloidosis infiltrative disease. The autopsy findings substantially aided understanding the immediate cause of death.

Entities:  

Mesh:

Year:  2018        PMID: 29937538      PMCID: PMC6047570          DOI: 10.12659/AJCR.908561

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


Background

Fat embolism syndrome (FES), a well-known complication of orthopedic and trauma surgery [1-4], describes a characteristic and clinically recognizable systemic reaction following a massive release of fat into the circulation that can lead to cardiorespiratory insufficiency and multiorgan failure. The traditional triad of FES, which can be subclassified as subclinical, non-fulminant, and fulminant [5], consists of respiratory failure, altered mental status, and skin petechiae [6,7]. Gurd and Wilson and, later on, Schonfeld, proposed a series of criteria to help the clinician recognize FES [8,9]. The high incidence of fat embolization during cemented arthroplasty is consistent with a substantial increase of intramedullary pressures after cement pressurization, forcing fat and bone marrow into the circulation. However, several cases of FES have been reported following cementless arthroplasty [2,10-12]. The incidence rate seems to be less than 1% in retrospective reviews, while it ranges from 10% to 30% in prospective studies [13,14]. The incidence rate of fat embolism at post-mortem appears to be as high as 20%, exceeding by several times the clinically suspected rate. This disparity has given rise to the concept of an “iceberg effect”, confirmed by the use of transesophageal echo-cardiography, suggesting a very high incidence of fat embolism during orthopedic surgery, even though the symptomatic forms remains relatively rare [13,15]. Mortality rates in the 1970s ranged from 10% to 20%, whereas more recent studies report mortality rates of 10% or less, mainly because of earlier diagnosis and advances in supportive care [16]. However, there is still little information regarding the occurrence of the fulminant FES in orthopedic surgery, especially in patients with no apparent cardiovascular risk factors. We believe that this topic is clinically relevant, and that greater effort should be made in recognizing this serious and fatal condition in order to improve the survival in these patients.

Case Report

We present the case of a 72-year-old man with osteoarthritis who underwent an elective right cementless total hip arthroplasty. His past medical history included mild emphysema and hypertension. Preoperative evaluation was consistent with an American Society of Anesthesiologists (ASA) score of II, of the complementary evaluation, only a right bundle branch block. Preoperative chest X-ray findings were unremarkable. The patient was put under general anaesthesia. The intra-operative course was uncomplicated. Two hours after the intervention, the patient lost consciousness and was found to be hypotensive, with reduced oxygen saturation. Urgent echocardiographic evaluation demonstrated a severe right heart dilatation. The patient died after numerous resuscitation attempts. Post-mortem examination revealed a severe cardiomegaly (with a cardiac mass of 640 g) as well as the presence of substenotic coronary vascular lumina with multifocal areas of mild to severe atherosclerosis. Cardiac valves were unremarkable. The abdominal aorta showed a localized dilatation, consistent with chronic aneurysm. The pulmonary arteries and major bronchi were unremarkable. The lungs were slightly edematous and congested. Brain examination findings were unremarkable. Microscopic examination of the lungs showed red blood cells marginalization and optically empty vacuolation within capillaries and arterioles (Figure 1A). Sudan III staining confirmed the presence of fat emboli, appearing as orange intravascular globules (Figure 1B). Microscopic examination of the heart revealed thickened wall of intramyocardial arterioles with subsequent bulging in the lumen (Figure 1C). Congo red staining and typical apple-green birefringence under polarized light confirmed the presence of amyloid deposits within the vessel wall (Figure 1D). Amyloid deposits consisted of TTR (transthyretin) protein. There was no sign of amyloid deposits within the myocardium or in other organs evaluated. The final cause of death was pulmonary fat embolism associated with vascular heart amyloidosis and coronary atherosclerosis.
Figure 1.

(A) Hematoxylin and eosin (H&E) stain at 25× magnification: marginalization of the erythrocytes associated with an optically empty vacuolation within lung vessels. (B) Sudan III stain at 25× magnification: frozen lung tissue with fat emboli that appear as orange intravascular globules. (C) H&E stain at 25× magnification: myocardial arterioles with thickened walls and amorphous deposits. (D) Congo Red stain at 10× magnification: amorphous pink deposits at light microscopy showing apple-green birefringence under polarized microscopy, consistent with amyloidosis.

Discussion

Although FES is relatively rare, it is a potentially life-threatening condition and its diagnosis should be considered in all patients with a postoperative change in respiratory or neurologic status after either cemented or cementless arthroplasty. FES cannot always be accurately diagnosed on clinical grounds only, because of elusive symptoms in milder forms and sudden onset with fulminant clinical course in the most severe ones. Lack of universal criteria for diagnosis and limited studies can also make the post-mortem diagnosis difficult to ascertain [17]. A widely used histological classification (introduced by Falzi and modified by Janssen) provides a four-grade scoring system for pulmonary fat embolism (Table 1). Falzi-grade III can usually be stated as a direct cause of death without concomitant factors; however, it is also accepted that less pronounced fat embolism can lead to acute right heart failure in patients with pre-existing cardiac disease [17]. Engorgement of lung micro-circulation by fat globules results in increased pulmonary vascular resistance, which in turn causes an increased workload of the right heart. If there is previous heart damage (such as that caused by an infiltrative disease), the ability to overcome this resistance is compromised and heart failure is more likely to occur, even in case of minor embolism. In the case described above, the fatal outcome was due to a moderate fat pulmonary embolism (grade II sec. Falzi) and to cardiac vascular disease, which strongly contributed to making the heart incapable of supporting the sudden increase in vascular resistance due to the fat embolism. Particularly, heart involvement by amyloid deposition is a common feature of systemic amyloidosis, but can also occur as a localized phenomenon [18], and involvement of the intramyocardial vessels has been associated with clinically significant cardiac disease [19]. However, because of its rarity, its insidious onset, and the vague nature of symptoms, cardiac amyloidosis is hard to recognize and the diagnosis may not be made in a patient undergoing anaesthesia and surgery for an apparently straightforward problem. It is important to point out that, in the presence of cardiac amyloidosis, several unexpected complications (including heart failure) may arise, either before the operation or in the postoperative period, especially if a surgical complication (such as the fat embolism in our patient) occurs [20]. A variety of diagnostic modalities (e.g., endomyocardial biopsy, echocardiography, electrocardiography (ECG), cardiovascular magnetic resonance imaging, radionuclide imaging) are available, but no single test is sufficient by itself; hence, early and accurate diagnosis remains difficult [21]. ECG findings associated with amyloidosis include low-voltage QRS complexes, conduction defects, and pseudoinfarction patterns. Despite the presence of right bundle branch block on the ECGs of our patient, given the absence of other symptoms, preoperative cardiovascular risk was impossible to accurately assess with the standard preoperative evaluation.
Table 1.

Grading of pulmonary fat embolism (PFE) sec. Falzi.

GradeEmboli shapeEmboli frequency*
I – light PFEDropSporadic
II – moderate PFESausageMultiple, disseminated
III – massive PFEAntlerNumerous, everywhere
0 – no PFEVery rare

Per field of view at 25× magnification.

Conclusions

Severe complications of pulmonary fat embolism depend on multiple risk factors, and comorbidities may play a paramount role in the overall clinical picture. Greater effort should be made to identify in advance any relevant, although insidious, preoperative risk factor such as amyloidosis.
  21 in total

1.  Fat embolism syndrome after cementless total hip arthroplasty.

Authors:  J J Gelinas; R Cherry; S J MacDonald
Journal:  J Arthroplasty       Date:  2000-09       Impact factor: 4.757

Review 2.  Autopsy diagnosis of fat embolism syndrome.

Authors:  Peter Miller; Joseph A Prahlow
Journal:  Am J Forensic Med Pathol       Date:  2011-09       Impact factor: 0.921

Review 3.  Pathophysiology and management of the fat embolism syndrome.

Authors:  S Hofmann; G Huemer; M Salzer
Journal:  Anaesthesia       Date:  1998-05       Impact factor: 6.955

4.  Fatal marrow embolization following a porous-coated bipolar hip endoprosthesis.

Authors:  J S Arroyo; K L Garvin; M H McGuire
Journal:  J Arthroplasty       Date:  1994-08       Impact factor: 4.757

5.  Fat embolism syndrome: history, definition, epidemiology.

Authors:  Max Talbot; Emil H Schemitsch
Journal:  Injury       Date:  2006-10       Impact factor: 2.586

Review 6.  Cardiac amyloidosis: approaches to diagnosis and management.

Authors:  Harit V Desai; Wilbert S Aronow; Stephen J Peterson; William H Frishman
Journal:  Cardiol Rev       Date:  2010 Jan-Feb       Impact factor: 2.644

Review 7.  Evaluation and management of the cardiac amyloidosis.

Authors:  Joseph B Selvanayagam; Philip N Hawkins; Biju Paul; Saul G Myerson; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

Review 8.  Fat embolism.

Authors:  Shamsuddin Akhtar
Journal:  Anesthesiol Clin       Date:  2009-09

9.  Clinical significance of histopathologic patterns of cardiac amyloidosis.

Authors:  T J Smith; R A Kyle; J T Lie
Journal:  Mayo Clin Proc       Date:  1984-08       Impact factor: 7.616

10.  Amyloidosis and Anesthesia.

Authors:  Zara Wani; Dev Kumar Harkawat; Meenaxi Sharma
Journal:  Anesth Essays Res       Date:  2017 Jan-Mar
View more
  2 in total

1.  Clinical Characteristics of Six Cases of Tracheobronchopathia Osteochondroplastica.

Authors:  Rong Guo; Mingming Zhou; Xiaohui Wei; Ling Niu
Journal:  Can Respir J       Date:  2020-06-16       Impact factor: 2.409

2.  Risk factors for acute pulmonary embolism in patients with off-pump coronary artery bypass grafting: implications for nursing.

Authors:  Jinli Zhou; Xiuhong Cao; Yeping Du; Yan Shi; Weiwei Pan; Suhong Jia
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.